JPMorgan Chase & Co. Buys 52,169 Shares of OptimizeRx Co. (NASDAQ:OPRX)

JPMorgan Chase & Co. boosted its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 670.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 59,952 shares of the company's stock after purchasing an additional 52,169 shares during the period. JPMorgan Chase & Co. owned 0.33% of OptimizeRx worth $291,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of OPRX. Barclays PLC raised its stake in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Royce & Associates LP bought a new stake in OptimizeRx during the fourth quarter worth $5,198,000. SG Americas Securities LLC bought a new stake in OptimizeRx during the fourth quarter worth $51,000. Perkins Capital Management Inc. lifted its stake in OptimizeRx by 4.4% in the fourth quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock valued at $514,000 after acquiring an additional 4,450 shares during the last quarter. Finally, Greenwood Capital Associates LLC increased its stake in shares of OptimizeRx by 31.5% during the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company's stock worth $431,000 after purchasing an additional 21,240 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, Director James Paul Lang bought 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The stock was bought at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. B. Riley raised OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, OptimizeRx presently has a consensus rating of "Moderate Buy" and an average target price of $9.06.

OptimizeRx Price Performance

OptimizeRx stock opened at $10.05 on Friday. The company has a market capitalization of $185.82 million, a price-to-earnings ratio of -7.56 and a beta of 1.18. The stock's 50 day moving average is $7.69 and its 200-day moving average is $6.19. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 12 month low of $3.78 and a 12 month high of $14.13.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.